LIDDS releases corporate capital markets agenda

UPPSALA, SWEDEN – LIDDS AB (publ) today announced the agenda for Capital Markets Day to be held on March 9, 2022, for investors, analysts and the media.

Agenda Capital Markets Day 2022

15.00-15.10 welcome – Nina Herne, CEO
3:10-3:45 p.m. Overview of LIDDS company strategy and drug delivery technology – Nina Herne, CEO
3:45-4:45 p.m. Update on LIDDS pipeline and clinical programs – Johan Harmenberg, CMO
4:45-4:55 p.m. Break
4:55-5:15 p.m. Financial update – Jenni Björnulfson, Chief Financial Officer
17.15-18.00 Q&A session – Nina Herne, CEO, Johan Harmenberg, CMO, Jenni Björnulfson, CFO, Mattew Lindon, CSO and Jan Törnell, Chairman of the Board.

Capital Markets Day is a hybrid event. Entrants are welcome to participate physically, at Redeye’s office, Mäster Samuelsgatan 42, 10th Floor, Stockholm, Sweden, or digitally.

Registration for Capital Markets Day is done by email at [email protected] The last day to register is March 7, 2022. No pre-registration is required to watch the webcast. The webcast will be available on: https://www.redeye.se/events/835119/capital-markets-day-lidds-pharma

LIDDS processes the personal data you provide in your notification in accordance with our privacy policy. Throughout the event, local restrictions related to Covid-19 will be respected. For this reason, the event will become fully digital if necessary.

The presentation will be conducted in English and will also be available on the Company’s website, www.liddspharma.com after the event.

For more information, please contact

Nina Herne, CEO
Telephone: +46 (0)70 714 74 57,
Email: [email protected]

Jenni Björnulfson, Chief Financial Officer
Telephone: +46 (0)708 55 38 05
Email: [email protected]

The LIDDS Certified Advisor is Redeye AB.
Phone : [+46] 8 121 576 90
Email: [email protected]

The information was submitted for publication, through the aforementioned contact person, on March 4, 2022 at 5:30 p.m. CET.

LIDDS in a nutshell:
LIDDS is a Swedish drug delivery company based on proprietary NanoZolid® technology. With NanoZolid®, LIDDS can formulate drugs for local administration, with sustained and controlled release for up to six months. The technology is versatile, can be used in different drug classes and solves problems in many indication areas. LIDDS offers the NanoZolid® technology to partners and has developed its own oncology-focused pipeline, where the technology delivers a local, high dose of drug, delivered over time with very limited side effects. LIDDS has a large pipeline with several projects in clinical development, both in early and late-stage clinical development, and projects about to enter clinical development. The company is listed on the Nasdaq First North Growth Market.